- Ongoing, recruitingTherapeutic confirmatory (Phase III)
OPTI-TREX - Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients
The OPTI-TREX study is looking at how to give a blood-thinning medicine called enoxaparin to children after a kidney transplant. The goal is to find the best dose to prevent blood clots in the new kidney and help it work well.
For: Allograft vascular thrombosisFrance - RecruitingPHASE4
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
This study looks at how to treat blood clots in cancer patients with low blood platelet counts. We're testing two approaches: a full dose of blood thinners with platelet transfusions, or a lower dose of blood thinners without transfusions, to see which is safest and most effective.
For: Cancer-associated Thrombosis · ThrombocytopeniaCanada - RecruitingPHASE2
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
This study is looking at a new combination treatment for people with severe liver disease (cirrhosis) who have recently been in hospital. We want to see if combining two existing medicines, albumin and enoxaparin, is safe and helps improve outcomes after leaving the hospital.
For: Liver Cirrhosis · Decompensated Cirrhosis of Liver · Acute on Chronic Liver Failure (ACLF)France · Germany · Italy - Active not recruitingPHASE1
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
This study is testing a new medicine called Andexanet. It's for healthy people aged 18 to 55. We want to see how Andexanet works with common blood thinners like Rivaroxaban and Apixaban, and if it affects another blood thinner called Enoxaparin. This helps doctors understand how to use Andexanet safely.
For: Healthy ParticipantsGermany · United Kingdom